Reproductive adverse events in patients with non-Hodgkin lymphoma treated with chemotherapeutic regimens including cyclophosphamide, doxorubicin, vincristine, prednisone or CHOP with rituximab: A systematic review and meta-analysis

Abstract

The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP) is the first-line treatment for non-Hodgkin lymphoma (NHL). NHL patients treated with CHOP/R-CHOP have a high risk of reproductive adverse events. The aim of this article was to evaluate the reproductive toxicity of regimens and make further suggestions on reproductive protection. We systematically searched with appropriate terms from January 1980 to June 2021 for observational studies in patients treated with CHOP/R-CHOP, without any language restriction. We conducted meta-analyses of one-sample proportions of patients suffering reproductive adverse events after using CHOP/R-CHOP. In addition, subgroup analyses were performed to determine the effect of sex. Nine articles involving 331 patients were included in the meta-analysis, and the pooled proportion of reproductive adverse events was computed to be 22.3% (95% confidence interval [CI] 11.4%–33.2%; heterogeneity test Q = 65.3; τ² = 0.0231; I² = 87.70%; p < 0.001) using the random-effects model. And, the pooled proportion of male gonadal toxicity was 29.2% (95% CI 11.0%–47.4%; heterogeneity test Q = 46.65; τ² = 3.055; I² = 89.3%; p < 0.0001). The pooled proportion of female gonadal toxicity was 16.5% (95% CI 8.5%–24.5%; heterogeneity test Q = 18.6; τ² = 0.0112; I² = 67.8%; p = 0.005). The findings suggest that NHL patients have a relatively high risk of reproductive adverse events after treatment with CHOP/R-CHOP. Men are more likely to have gonadal damage than women. Evaluation of reproductive function is particularly necessary both before and after treatment. Some reproductive protection strategies implemented for patients who want to preserve their fertility.

Keywords

antineoplastic combined chemotherapy protocols / adverse effects antineoplastic combined chemotherapy protocols / therapeutic use cyclophosphamide / adverse effects humans reproduction / tumor

References

[1] Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328(14): 1002-1006.

[2] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4): 235-242.

[3] Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA A Cancer J Clin. 2020; 70(6): 443-459.

[4] Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med. 1975; 82(1): 84-95.

[5] Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980; 93(1): 109-114.

[6] Queirós V, Azeiteiro UM, Soares AMVM, Freitas R. The antineoplastic drugs cyclophosphamide and cisplatin in the aquatic environment - review. J Hazard Mater. 2021; 412:125028.

[7] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339(jul21 1):b2535.

[8] Porritt K, Gomersall J, Lockwood C. JBI's systematic reviews: study selection and critical appraisal. Am J Nurs. 2014; 114(6): 47-52.

[9] Armitage JO, Fyfe MA, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol. 1984; 2(8): 898-902.

[10] Müller U, Stahel RA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 1993; 4(5): 399-402.

[11] Pryzant RM, Meistrich ML, Wilson G, Brown B, McLaughlin P. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol. 1993; 11(2): 239-247.

[12] Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol. 1994; 68(3): 105-110.

[13] Dann EJ, Epelbaum R, Avivi I, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod. 2005; 20(8): 2247-2249.

[14] Elis A, Tevet A, Yerushalmi R, et al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006; 47(4): 623-627.

[15] Meissner J, Tichy D, Dietrich S, et al. Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br J Haematol. 2014; 166(4): 612-615.

[16] Meissner J, Tichy D, Katzke V, et al. Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol. 2015; 26(8): 1771-1776.

[17] Pallotti F, Pelloni M, Faja F, et al. Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study. Hum Reprod. 2021; 36(1): 16-25.

[18] Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5): 379-391.

[19] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-560.

[20] Kim S, Kim SW, Han SJ, et al. Molecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage. Int J Mol Sci. 2021; 22(14):7484.

[21] Potnuri AG, Allakonda L, Lahkar M. Crocin attenuates cyclophosphamide induced testicular toxicity by preserving glutathione redox system. Biomed Pharmacother. 2018; 101: 174-180.

[22] Senturia YD, Peckham CS, Peckham MJ. Children fathered by men treated for testicular cancer. Lancet. 1985; 2(8458): 766-769.

[23] Dodds L, Marrett LD, Tomkins DJ, Green B, Sherman G. Case-control study of congenital anomalies in children of cancer patients. Br Med J. 1993; 307(6897): 164-168.

[24] Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol. 1999; 33(1): 29-33.

[25] Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet. 1998; 62(1): 45-52.

[26] Meistrich ML, Byrne J. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. Am J Hum Genet. 2002; 70(4): 1069-1071.

[27] Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer. 2009; 53(2): 261-266.

[28] Green DM, Liu W, Kutteh WH, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014; 15(11): 1215-1223.

[29] Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015; 13(4): 277-290.

[30] Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016; 15(10): 955-963.

[31] Østensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatol. 2008; 47(Suppl 3): iii28-iii31.

[32] Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996; 87(7): 3045-3052.

[33] Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility. Reprod Biol Endocrinol. 2018; 16(1): 112.

[34] Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(19): 2500-2510.

[35] Ginsberg JP. Educational paper: the effect of cancer therapy on fertility, the assessment of fertility and fertility preservation options for pediatric patients. Eur J Pediatr. 2011; 170(6): 703-708.

[36] Bates GE, Taub RN, West H. Fertility and cancer treatment. JAMA Oncol. 2016; 2(2): 284.

[37] Ginsberg JP, Carlson CA, Lin K, et al. An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety. Hum Reprod. 2010; 25(1): 37-41.

[38] Carlson CA, Kolon TF, Mattei P, et al. Developing a hospital-wide fertility preservation service for pediatric and young adult patients. J Adolesc Health. 2017; 61(5): 571-576.

[39] Depalo R, Falagario D, Masciandaro P, et al. Fertility preservation in males with cancer: 16-year monocentric experience of sperm banking and post-thaw reproductive outcomes. Ther Adv Med Oncol. 2016; 8(6): 412-420.

[40] van der Kaaij MA, van Echten-Arends J, Heutte N, et al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Hum Reprod. 2014; 29(3): 525-533.

RIGHTS & PERMISSIONS

2024 The Authors. Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children's Hospital of Chongqing Medical University.